CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 190 enrolled
Drug / intervention
Marcaine, Duramorph , ketorolac +2 moredrug
Likely dose
Marcaine, Duramorph , ketorolac 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03693404
NCT03693404Phase 4Completed

Effects of a Surgical Site Injection on Pain Scores and Narcotic Use After Orthopaedic Trauma Surgery

NYU Langone Health·interventional·Posted Oct 3, 2018·Updated Jul 21, 2022

In Brief

A Phase 4 clinical trial evaluating Marcaine, Duramorph , ketorolac, Bupivacaine (Marcaine), and 1 other intervention for Pertrochanteric Fracture. Completed, enrolled 190 participants across 1 site.

Detailed Summary

This is a phase I, randomized, single-blind, placebo-controlled, single-center study of the effects of surgical site injection on pain and narcotic utilization in participants who undergo surgery for lower extremity fractures. 200 participants with lower extremity fractures who are admitted for operative fixation will be included in the study. Participants will be randomized to receive either a pain cocktail injection around the fracture site and surrounding tissues or control (no injection). An analysis of pain scores, rehabilitation progress, length of stay, narcotic utilization, and satisfaction scores will be performed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 3, 2018
Enrollment StartDec 1, 2018
Primary CompletionJun 5, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.7 years ago

Interventions

Marcaine, Duramorph , ketorolacdrug

Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.

Bupivacaine (Marcaine)drug

0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.

General Anestheticsdrug

Placebo group will only receive standard of care general anesthesia